Vice Chairman, Department of Cardiovascular Medicine, Cleveland Clinic Director, C5Research (Cleveland Clinic Coordinating Center for Clinical Research) Director, Center for Clinical Research and Vice Chairman, Lerner Research Institute Professor of Me
Cardiology
Dr. Abraham M. Lincoff, MD
|
|
Give Review
Abraham Lincoff practices Cardiology. He graduated from Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine is ranked 3 in research and 29 in primary care medicine He over the years received 16 awards: "CMS Meaningful Use Stage 1 Certification", "Maria and Sam Miller Professional Excellence Award - Scientific Achievement Award in Clinical Research", "American College of Cardiology/Bristol Laboratories Affiliate Travel Award", "Research Day Award for Clinical Fellows", "Fellow", "With University Honors", "Alpha Omega Alpha", "Franklin Paine Mall Award for Cell Biology and Anatomy", "Lange Medical Publishers Student Award", "Andrew Carnegie Society Scholarship for Carnegie Institute of Technology", "Tau Beta Pi Honorary Engineering Fraternity", "American Institute of Chemical Engineers Outstanding Student Award", "Atlantic Richfield Award", "Universal Oil Products Foundation Award", "Babcock and Wilcox Aid to Education Award" and "American Society of Chemists Award". Abraham Lincoff has written publications. He has 97 publications published with PubMed. The lastest publication is: 'Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.' Dr. Abraham M. Lincoff is registered with Medicare.
Publications
- Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous Coronary intervention (REGULATE-PCI): a randomised clinical trial.
- What Role for Glycoprotein IIb/IIIa Inhibition in Contemporary Coronary Intervention?
- Effect of Anemia on Frequency of Short- and Long-Term Clinical Events in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strate...
- Effects of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on renal function in patients with stage 3 chronic kidney Disease and ty...
- Incidence and Impact of Totally Occluded Culprit Coronary Arteries in Patients Presenting With Non-ST-Segment Elevation Myocardial Infarction.
- Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous Coronary intervention.
- β-Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction: Post Hoc Analysis From the CHARISMA Trial.
- Association of glycemic control with mortality in patients with diabetes mellitus undergoing percutaneous Coronary intervention.
- Heparin monotherapy for percutaneous Coronary intervention?
- Cardiovascular safety evaluation in the development of new drugs for diabetes mellitus.
- Impact of antithrombotic treatment on short-term outcomes after percutaneous Coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and...
- Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for Acute anterior ST-segment elevation myocardial infa...
- Effect of aleglitazar on cardiovascular outcomes after Acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
- Managing Acute coronary syndromes: decades of progress.
- Impact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis of Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: An Analysis From the...
- Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis.
- Varespladib and cardiovascular events in patients with an Acute coronary syndrome: the VISTA-16 randomized clinical trial.
- Interventional cardiology: Does an optimal antithrombotic regimen for PCI exist?
- Evaluation of the dual peroxisome proliferator-activated receptor alpha/gamma agonist aleglitazar to reduce cardiovascular events in patients with Acute coronary syndr...
- 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable Angina/non-ST-elevation myocardial infarction:...
- Cause of Death Within 30 Days of Percutaneous Coronary Intervention in an Era of Mandatory Outcome Reporting.
- Management of the patient with diabetes and Coronary artery disease: a contemporary review.
- Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with Acute coronary syndromes: insigh...
- Here and now--state of the art: optimal antithrombotic strategy for percutaneous Coronary intervention-panel discussion.
- Predictive models for short- and long-term adverse outcomes following discharge in a contemporary population with Acute coronary syndromes.
- Percutaneous Coronary revascularization in Coronary artery disease: lessons from a single center experience.
- Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
- The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
- Antiplatelet agents in ischemic Heart disease.
- 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable Angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline a...
- Defining Heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward.
- Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Obs...
- Primary and secondary prevention of cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-...
- Thrombin-receptor antagonist vorapaxar in Acute coronary syndromes.
- Managing adverse effects and drug-drug interactions of antiplatelet agents.
- Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR...
- Impact of bleeding on mortality after percutaneous Coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI l...
- Comparison of Outcomes of Unprotected Left Main Versus Multivessel Coronary Artery Interventions.
- Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with Acute coronary syndromes: the ACUITY ...
- Percutaneous coronary intervention for Acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose u...
- 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline...
- 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: ...
- 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction A...
- 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)...
- Enhanced prediction of mortality after percutaneous Coronary intervention by consideration of general and neurological indicators.
- Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous Coronary intervention.
- Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with Acute coronary syndrome.
- Predictive value of C-reactive protein on 30-day and 1-year mortality in Acute coronary syndromes: an analysis from the ACUITY trial.
- Bleeding complications of unfractionated heparin.
- Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis.
- Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular Disease in patients with diabetes mellitus.
- Strategies for the development of new PPAR agonists in diabetes.
- A rare complication of infective Endocarditis.
- The use and limitations of unfractionated heparin.
- Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis.
- Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Int...
- Platelet functions beyond hemostasis.
- Intravenous platelet blockade with cangrelor during PCI.
- Platelet inhibition with cangrelor in patients undergoing PCI.
- Smoking, clopidogrel, and mortality in patients with established cardiovascular Disease.
- Standardized reporting of bleeding complications for clinical investigations in Acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidi...
- Prasugrel for Acute coronary syndromes: faster, more potent, but higher bleeding risk.
- Magnitude and consequences of missing the Acute infarct-related circumflex artery.
- Outcomes of patients with Coronary artery perforation complicating percutaneous Coronary intervention and correlations with the type of adjunctive antithrombotic thera...
- Gastrointestinal bleeding in patients with Acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization ...
- The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
- Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with Acute coronary...
- The association between early ventricular Arrhythmias, renin-angiotensin-aldosterone system antagonism, and mortality in patients with ST-segment-elevation myocardial ...
- Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular Disease in patients with type 2 diabetes (SYNCH...
- Drug-eluting stent fracture and Acute coronary syndrome.
- Choice of arterial access site and outcomes in patients with Acute coronary syndromes managed with an early invasive strategy: the ACUITY trial.
- Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia.
- Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation Acute coronary syndromes undergoing pe...
- Outcomes following pre-operative clopidogrel administration in patients with Acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Cath...
- Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end po...
- Early stent thrombosis in patients with Acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Tri...
- Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive man...
- Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with Acute myocardial infarction.
- Pharmacologic inhibition of platelet function: correlation between in vitro tests of platelet function and clinical outcomes.
- Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with Acute coronary syndromes undergoing percutaneous coronary interve...
- Antithrombotic therapy for non-ST-segment elevation Acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed...
- Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
- Acute pharmacological conversion of atrial fibrillation to sinus rhythm: is short-term symptomatic therapy worth it? A report from the December 2007 Meeting of the Ca...
- Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation Acute coronary syndromes man...
- Comparison of pioglitazone vs glimepiride on progression of Coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
- Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and Coronary artery disease: the STRADIVARIUS randomized controlled trial.
- Should patients on long-term warfarin take aspirin for Heart disease?
- Meta-analysis comparing reported frequency of atrial fibrillation after Acute coronary syndromes in Asians versus whites.
- Antithrombotic strategies in patients with Acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
- Impact of female sex on death and bleeding after fibrinolytic treatment of Myocardial infarction in GUSTO V.
- Predictors and impact of major hemorrhage on mortality following percutaneous Coronary intervention from the REPLACE-2 Trial.
- Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
- Off-pump Coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies.
- ACC/AHA 2007 guidelines for the management of patients with unstable Angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/Amer...
- Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous Coronary intervention via the femoral approach.
- ACC/AHA 2007 guidelines for the management of patients with unstable Angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/Amer...
Schools
Johns Hopkins University School Of Medicine
Beth Israel Hospital
Cleveland Clin Found
University Of Michigan
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Dissection
- View All
Doctors Specialties
- Cardiology
- Interventional Cardiology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- CareSource
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health America PPO
- Emblem Health
- First Health (Coventry Health Care) PPO
- Golden Rule
- GEHA
- Health Alliance
- Medicare Advantage PFFS
- Choice Care PPO
- Kaiser Permanente
- Medicaid
- Medical Mutual of Ohio POS
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Paramount
- Priority Health
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- WellCare
- Wells Fargo Insurance
Awards
- CMS Meaningful Use Stage 1 Certification
- Maria and Sam Miller Professional Excellence Award - Scientific Achievement Award in Clinical Research
- American College of Cardiology/Bristol Laboratories Affiliate Travel Award
- Research Day Award for Clinical Fellows
- Fellow
- With University Honors
- Alpha Omega Alpha
- Franklin Paine Mall Award for Cell Biology and Anatomy
- Lange Medical Publishers Student Award
- Andrew Carnegie Society Scholarship for Carnegie Institute of Technology
- Tau Beta Pi Honorary Engineering Fraternity
- American Institute of Chemical Engineers Outstanding Student Award
- Atlantic Richfield Award
- Universal Oil Products Foundation Award
- Babcock and Wilcox Aid to Education Award
- American Society of Chemists Award
Education
-
Cleveland Clinic Foundation -
University of Michigan Hospitals and Health Centers -
Beth Israel Deaconess Medical Center -
Johns Hopkins University School of Medicine
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1427141902 | |
| NPPES Provider LastName | LINCOFF | |
| NPPES Provider FirstName | ABRAHAM | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Cardiology | |
| Total Claim Count | 448.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1427141902 |
| Last Name Of The Provider | LINCOFF |
| First Name Of The Provider | ABRAHAM |
| View All |
Similar Doctors
|
|
Dr. Bruce D. Lindsay, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anjli P. Maroo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eiran Z. Gorodeski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amena M. Hussain, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lloyd Greene, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saurabh Jha, MD |
|
|
Dr. James A. Patterson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Balaji K. Tamarappoo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nina Rashedi, MD |
|
|
Dr. Dermot M. Phelan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elad Asher, MD |
|
Dr. Hiram G. Bezerra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Lee, MD |
|
|
Dr. Joseph V. Joson, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Juan C. Plana Gomez, MD
This Doctor is OpenDoctor Recommended.
|